Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 9/20 | 0.38 |
| ▸ | CDK14 | O94921 | 4/20 | 0.37 |
| ▸ | CCNY | Q8ND76 | 4/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564164 | 0.95 | TP53 (0.36) | CHRM4TP53POLBATM | |
| SCHEMBL3564160 | 0.95 | TP53 (0.36) | CHRM4TP53POLBATM | |
| Trifluoroacetic Acid SCHEMBL3572477 | 0.89 | CDK14 (0.38) | CHRM4CDK14CCNYATM | |
| Trifluoroacetic Acid SCHEMBL3572482 | 0.89 | CDK14 (0.38) | CHRM4CDK14CCNYATM | |
| Trifluoroacetic Acid SCHEMBL4694994 | 0.89 | CDK14 (0.38) | CHRM4CDK14CCNYATM | |
| Trifluoroacetic Acid SCHEMBL3566373 | 0.86 | PDK2 (0.40) | CDK14CCNY | |
| Trifluoroacetic Acid SCHEMBL3566369 | 0.86 | PDK2 (0.40) | CDK14CCNY | |
| Trifluoroacetic Acid SCHEMBL3571095 | 0.85 | PDK2 (0.36) | CHRM4CDK14CCNY | |
| Trifluoroacetic Acid SCHEMBL3571100 | 0.85 | PDK2 (0.36) | CHRM4CDK14CCNY | |
| Trifluoroacetic Acid SCHEMBL3570807 | 0.83 | SYK (0.35) | CDK14CCNY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713994-B2 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof | WYETH LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | WYETH (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | SULT1E1, RECQL, HAX1 | CHRM4 3103/4885CDK14 2498/4885CCNY 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.